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ABSTRACT 
A simple, selective, precise high performance thin layer chromatography (HPTLC) method with densitometry at λ= 205 nm was dev eloped and 
validated for simultaneous determination of Pregabalin and Amitriptyline Hydrochloride in pharmaceutical dosage form. Chromatographic 
separation of the drugs were performed on aluminum plates precoated with silica gel 60 F254 used  as stationary phase and the chromatogram 
was developed using Toluene: Methanol: Formic acid (7: 2.5: 0.5 v/v/v) and 20 ml of mobile phase was used per chromatography run. The 
system was found to give a compact band for Pregabalin (R f =0.27±0.03) and Amitriptyline Hydrochloride (Rf =0.68±0.03). The validated lowest 
limit of detection was 45.097ng/spot and 12.614ng/spot wherenas lowest limit of quantification was 136.659ng/spot and 38.224ng/spot for 
Pregabalin and Amitriptyline Hydrochloride respectively. The percentage recovery for Pregabalin was found to be 99.91 (at 50%), 99.39 (at 
100%), 99.27(at 150%) and 100.42 (at 50%), 100.63 (at 100%), 100.97(at 150%) for Amitriptyline Hydrochloride. Statistical analysis proved 
that the method is selective, precise and accurate for the estimation of Pregabalin and Amitriptyline Hydrochloride.  
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1. INTRODUCTION 
 Pregabalin is (S)-4-amino-3-(2-methylpropyl) butyric acid 
(Fig.1)1 2 which is analogue of gabapentine, is more potent 
but very similar. It is used as anti-epileptic by binding with 
high affinity to the alpha-2-deltasite (subunit of calcium 
channels) 3. Pregabalin also affects chemicals in the brain that 
send pain signals across the nervous system. Pregabalin is 
used to treat pain caused by fibromyalgia, or nerve pain in 
people with diabetes (diabetic neuropathy), herpes zoster 
(post-herpetic neuralgia), or spinal cord injury 4. 
 
Figure 1: Pregabalin 
Mol Formula: C8H17NO2     Mol Weight: 159.229 g/mol 
Amitriptyline, 3-(10, 11-dihydro-5H-dibenzo [a, d] 
cycloheptene-5-ylidene)-N, N-dimethyl-1-Propanamine 
hydrochloride (Fig.2) 2 is one of the most anticholinergic and 
sedative of the TCAs. Because it lacks the ring-electron–
enriching nitrogen atom of imipramine, metabolic 
inactivation mainly proceeds not at the analogous 2-position 
but at the benzylic 10-position (i.e.,tolune-like metabolism 
predominates). Because of the 5-exocyclic double bond, E- 
and Z-hydroxy isomers are produced by oxidation 
metabolism4. It is tricyclic antidepressants which can elevate 
mood in depressive illness5 6. Amitriptyline increases the 
levels of chemical messengers in the brain that help in 
regulating the mood and treat depression7. 
 
Figure 2: Amitriptyline Hydrochloride 
Mol Formula: C20H24ClN    Mol Weight: 313.864 g/mol 
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2. EXPERIMENTAL 
2.1 Reagents and chemicals 
Pregabalin and Amitriptyline Hydrochloride were obtained 
as gift sample from Unichem laboratories Ltd, 
Pharmaceutical Company in Goa Industrial Estate, Goa, India. 
Toluene, Methanol, Formic acid was purchased from Merck 
Ltd. (Mumbai, India) 
2.3 Instrumentation 
CAMAG HPTLC instrument was used in this method. CAMAG 
HPTLC is equipped with CAMAG TLC scanner-3, Linnomate 5 
Automatic sample applicator controlled by WINCATS 
software (1.4.2 version). Aluminum plates precoated with 
silica gel 60 F254 HPTLC plates (10 X 10cm, layer thickness 
250 µm, E.MERCK) 
 
Table 1: Optimized chromatographic conditions 
Stationary phase precoated TLC plates  : Silica gel 60 F254 
Mobile phase                   : Toluene: Methanol: Formic acid 
“Mobile phase ratio (%v/v/v)    : 7.5:2:0.5 
Saturation time               : 20 minutes. 
Slit dimension                 : 5.00 x 0.45 mm. 
Source of radiation        : Deuterium. 
Scan wavelength             : 205 nm. 
Rf values 
Pregabalin                                            : 0.27±0.03. 
Amitriptytline Hydrochloride       : 0.68±0.03. 
 
2.4 Selection of analytical wavelength 
From the standard stock solution further dilutions were 
made using methanol and scanned over the range of 200 - 
400 nm and the spectra was obtained. It was observed that 
both the drug showed considerable absorbance at 205 nm 
(Fig.3) 
 
Figure 3: Overlay UV-VIS Spectra of PRGB (10 µg/ml) and 
AMTR (10 µg/ml) 
2.5 Preparation of Standard stock solution: 
Standard stock solution of PRGB and AMTR were prepared 
separately by dissolving 10 mg of drug in 10 ml of methanol 
to get concentration of 1000 µg/ml. From the respective 
standard stock solution, working standard solution was 
prepared containing 375µg/ml (375ng/µl) of PRGB and 
50µg/ml (50ng/µl) of AMTR separately in methanol (Fig.4, 5, 
6)
  
 
Figure 4: Densitogram of mixed standard solution of AMTR (100 ng/spot) and PRGB (750 ng/spot) 
 
Figure 5: Densitogram of standard solution of AMTR (100 ng/spot) 
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Figure 6: Densitogram of standard solution of PRGB (750 ng/spot) 
 
2.6 Preparation of sample solution (Tablet Formulation 
Analysis):  
Twenty tablets each containing 10 mg of AMTR and 75 mg of 
PRGB was weighed and powdered (Each uncoated tablet 
contains Pregabalin IP 75 mg and Amitriptyline HCl IP 10 
mg). Powder equivalent to 10 mg of AMTR (75 mg of PRGB) 
was transferred to 10 ml volumetric flask and was diluted 
with methanol and volume made to 10 ml (1000 µg/ml of 
AMTR and 7500 µg/ml of PRGB) with methanol. Solution 
was filtered and further dilutions were made with mobile 
phase to get the final concentration of 50 µg/ml of AMTR 
and 375 µg/ml of PRGB. 2 µl volumes were applied on TLC 
plate to get concentration 100 ng/spot of AMTR and 750 
ng/spot of PRGB (Fig.7) 
 
 
Figure 7: Densitogram of test solution (Tablet Sample) of AMTR (100 ng/spot) and PRGB (750 ng/spot) 
 
2.7Assay 
Tablet formulation analysis was carried out as mentioned 
under section Tablet Formulation Analysis. Procedure was 
repeated for six times. Sample solution was applied and area 
was recorded for each drug. Concentration and % purity was 
determined from linear equation shown in (Table 1) 
 
Table 2: Assay results for PRGB and AMTR      
 
Sr. no. 
PRGB AMTR 
Peak 
area 
Amount 
Recovered 
(ng/spot) 
% 
Recovery 
Peak 
area 
Amount 
recovered 
(ng/spot) 
% 
Recovery 
1 4370.5 767.866 102.382 1945.5 101.728 101.728 
2 4317.5 742.783 99.038 1919.4 98.856 98.856 
3 4325.8 746.711 99.561 1928.7 99.879 99.879 
4 4310.2 739.328 98.577 1935.2 100.594 100.594 
5 4365.8 765.641 102.086 1942.8 101.430 101.430 
6 4297.4 733.270 97.769 1942.5 101.397 101.397 
Mean 4331.200 749.266 99.902 1935.683 100.647 100.647 
% RSD 0.695 1.904 1.903 0.520 1.102 1.102 
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2.8 Validation of Analytical Method8 9 10 11 
2.8.1 Linearity 
From the standard stock solution (1000 µg/ml) of PRGB and 
AMTR, solution was prepared containing 375 µg/ml of PRGB 
and 10 µg/ml of AMTR separately. Different volumes were 
applied on TLC plate to obtain linear range. Six replicates per 
concentration were applied. The linearity (relationship 
between peak area and concentration) was determined over 
the concentration range 375 - 2250 ng/spot for PRGB and 50 
- 300 ng/spot for AMTR. The results obtained are shown in 
(Table 3 and Fig.8) for PRGB and in (Table 4 and Fig.9) for 
AMTR.
 
Table 3: Linearity study of PRGB 
Replicates Concentrations of PRGB (ng/spot) 
375 750 1125 1500 1875 2250 
Peak Area 
1 3450.20 4358.60 5200.30 5987.24 6658.23 7548.19 
2 3490.50 4321.50 5218.23 5897.50 6625.49 7485.60 
3 3418.56 4385.24 5190.80 5854.70 6658.23 7454.23 
4 3501.00 4328.50 5240.12 5850.70 6628.90 7558.20 
5 3520.40 4335.70 5279.80 5867.27 6689.20 7538.10 
6 3558.20 4358.50 5290.12 5865.70 6638.90 7578.20 
Mean 3489.81 4348.01 5236.56 5887.19 6649.83 7527.09 
Std.dev. 49.77 23.85 41.22 51.70 23.84 47.28 
%RSD 1.43 0.55 0.79 0.88 0.36 0.63 
 
 
 Figure 8: Calibration curve for PRGB 
Table 4: Linearity study of AMTR 
 
Replicates 
Concentrations of AMTR (ng/spot) 
50 100 150 200 250 300 
Peak Area 
1 1450.90 1980.50 2420.45 2890.70 3268.80 3695.23 
2 1422.25 1995.27 2470.82 2841.68 3254.18 3715.75 
3 1412.50 1950.50 2450.80 2798.92 3279.52 3652.48 
4 1390.40 1917.50 2529.30 2860.70 3229.60 3749.00 
5 1395.60 1929.80 2438.40 2897.40 3250.70 3784.80 
6 1370.40 1919.50 2517.30 2910.50 3239.60 3759.00 
Mean 1407.01 1948.85 2471.18 2866.65 3253.73 3726.04 
Std.dev. 28.05 32.76 43.75 41.70 18.35 48.03 
%RSD 1.99 1.68 1.77 1.45 0.56 1.29 
       
 
Figure 9: Calibration curve for AMTR 
y = 2.1137x + 2748.8 
R² = 0.9982 
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2.8.2 Precision: 
The precision of the method was demonstrated by Intra-day 
and Inter-day variation studies. In the Intraday precision 
was found by carrying out the analysis of standard drugs at 
three different concentrations in the linearity range of the 
drugs for three times on the same day. Each concentration 
was applied in triplicates and % RSD was calculated. For the 
Inter day precision was found by carrying out the analysis of 
the standard drugs at three different concentrations in the 
linearity range of the drugs for three days and % RSD was 
calculated. The results obtained for Intraday and Inter day 
variations are shown in (Table 5, 6, 7, 8) 
  
Table 5: Intra-day precision study of PRGB 
Concentration 
(ng/spot) 
Area % Recovery 
Avg % Recovery ± 
SD 
Mean % Recovery 
±  % RSD 
1125 
5102.30 99.03981 
99.263 ± 1.697 
 
 
98.887 ± 1.222 
5070.2 97.68944 
5150.37 101.062 
1500 
5930.10 100.3975 
99.344 ± 0.958 5889.40 99.11342 
5870.70 98.52343 
1875 
6682.90 99.31914 
 
98.251 ± 0.965 
6630.50 97.99653 
6608.40 97.43871 
 
Table 6: Inter-day precision of PRGB 
Concentration 
(ng/spot) 
Area % Recovery 
Avg % Recovery ± 
SD 
Mean % Recovery 
±  % RSD 
1125 
5157.3 101.354 
101.107 ± 0.961 
99.832 ± 1.543 
5126.23 100.046 
5170.8 101.921 
1500 
5977.24 101.885 
99.968 ± 1.699 5897.5 99.369 
5874.7 98.650 
1875 
6658.23 98.696 
98.421 ± 0.477 6625.49 97.870 
6658.23 98.696 
 
Table 7: Intra-day precision study AMTR 
Concentration 
(ng/spot) 
Area % Recovery 
Mean % 
Recovery ± SD 
Mean % Recovery±              
% RSD 
150 
2390.2 100.4401 
99.241 ± 1.098 
99.301 ± 1.008 
 
2370.6 99.00235 
2360.8 98.28345 
 
200 
2804.3 98.1129 
99.574 ± 1.479 2830.5 99.55436 
2857.8 101.0563 
 
250 
3259.7 98.53433 
99.087 ± 0.673 3289.3 99.83715 
3267.8 98.89085 
                                  
Table 8: Inter-day precision study AMTR 
Concentration 
(ng/spot) 
Area % Recovery 
Avg % Recovery± 
SD 
Mean%                   
Recovery ±  % RSD 
150 
2420.45 102.659 
 
101.699 ± 1.159 
100.764 ± 1.117 
2411.82 102.026 
2389.8 100.411 
200 
2850.7 100.666 
100.834 ± 0.763 2841.68 100.169 
2868.92 101.668 
250 
3298.8 100.255 
99.758 ± 0.547 3274.18 99.172 
3289.52 99.847 
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2.8.3 Accuracy 
To check accuracy of the method, recovery studies were 
carried out by adding standard drug to sample at three 
different levels 50, 100 and 150 %. Basic concentrations of 
sample chosen were 2 µl of 375 µg/ml of PRGB and 2 µl of 50 
µg/ml of AMTR. These solutions were applied on TLC plates 
in triplicate to obtain the densitogram. The drug 
concentrations of PRGB and AMTR were calculated by using 
linearity equations of PRGB and AMTR. The results obtained 
are shown in (Table 9, 10) 
 
Table 9: Recovery studies of PRGB 
Level 
Conc. (ng/spot) 
Area 
% 
Recovery 
Mean % Recovery ± 
RSD Sample Std. 
50 % 750 375 
5130.5 100.226 
99.909  ± 0.468 5128.2 100.129 
5110.2 99.372 
100 % 750 750 
5910 99.763 
99.387  ± 0.336 5889.8 99.126 
5894.4 99.271 
150 % 750 1125 
6695.8 99.645 
99.273  ± 0.478 6687.5 99.435 
6659.9 98.739 
 
Table 10: Recovery studies of AMTR 
Level 
Conc. (ng/spot) 
Area 
% 
Recovery 
Mean % Recovery ± 
RSD Sample Std. 
50 % 100 50 
2398.5 101.049 
100.418 ± 0.621 2389.7 100.403 
2381.5 99.802 
100 % 100 100 
2855.4 100.924 
100.627 ± 0.269 2845.8 100.396 
2848.8 100.561 
150 % 100 150 
3314 100.924 
100.973 ± 0.488 3326.8 101.488 
3304.5 100.506 
 
 
2.8.4 Limit of detection (LOD) and Limit of Quantification 
(LOQ) 
LOD and LOQ were calculated as 3.3 σ/S and 10 σ/S 
respectively. Where (σ) is the standard deviation of the 
response (y-intercept) and (S) is the mean of the slop of 
calibration plot. The LOD values of PRGB and AMTR was 
found to be 45.097ng/spot and 12.614ng/spot respectively 
and the LOQ values were found to be 136.659ng/spot and 
38.224ng/spot. 
2.8.5 Robustness: 
Robustness of the method was determined by carrying out 
the analysis under conditions during which wavelength, 
chamber saturation time and time form application to 
development was altered and the effect on area was noted. 
The results obtained are shown in (Table 11). 
 
Table 11: Robustness study 
Drug 
% RSD Found for Robustness Study (peak area) 
Wavelength 
Chamber 
 Saturation Time 
(Min) 
Time form 
application to 
development 
204 205 206 19 20 21 0 30 60 
PRGB 1.011 0.562 0.646 0.794 0.647 0.775 0.806 0.584 1.088 
AMTR 0.858 0.756 1.106 1.796 1.245 1.857 1.755 1.045 0.878 
 
 
3. RESULT AND DISSCUSSION 
This study was aimed at the development of sensitive, 
economical and less time consuming HPTLC technique for 
the determination of Pregabalin and Amitriptyline 
Hydrochloride in pharmaceutical dosage form. Well resolved 
by the relevant ICH guidelines and other current regulatory 
guidelines. The chromatographic conditions were optimized 
to achieve the best resolution and peak shape for Pregabalin 
and Amitriptyline Hydrochloride. UV scanning at 200-400 
nm for both Pregabalin and Amitriptyline Hydrochloride 
show that 205 nm is the suitable wavelength for detection of 
drug (Fig.3). Different mobile phase in different proportion 
were tried and the mobile phase containing Toluene: 
Methanol: Formic acid (7: 2.5: 0.5 v/v/v) was selected as 
optimal for obtaining well resolved peaks of Pregabalin (Rf 
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=0.27±0.03) and Amitriptyline Hydrochloride (Rf 
=0.68±0.03) with acceptable system suitability parameters 
(Fig.4). The linearity (relationship between peak area and 
concentration) was determined over the concentration 
range 375 - 2250 ng/spot (r2 =0.999) for Pregabalin (Table. 
3 and Fig. 8) and 50 - 300 ng/spot (r2 =0.999) for 
Amitriptyline Hydrochloride (Table. 4 and Fig. 9). The LOD 
and LOQ were found to be 45.097, 12.614ng/spot, 136.659, 
38.224ng/spot respectively for Pregabalin and Amitriptyline 
Hydrochloride. The method was found to be precise based 
on the results obtained in the intraday and inter-day 
precision evaluation study. These results were expressed in 
terms of % RSD that was found to be less than 2 (Table 5, 6, 
7, 8). High recovery values followed by low % RSD value 
(<2) coupled with low standard deviation makes the 
proposed method highly suitable for accurate and precise 
determination of Pregabalin and Amitriptyline 
Hydrochloride in combined tablet dosage forms. Closeness 
of the amount found to the amount taken and low coefficient 
of variation value showed that the proposed method was 
accurate and precise. Recovery study conducted by HPTLC 
method was performed by spiking 50, 100 and 150 % of 
additional drug recovery of 99.91-99.39 % for Pregabalin 
and 100.42-100.97 % for Amitriptyline Hydrochloride as 
listed in (Table 9 and 10). To evaluate the robustness of the 
method, the parameters selected were varied at three levels. 
The results indicate that less variability in retection time 
were observed. (Table 11) 
4. CONCLUSION 
Introducing HPTLC into pharmaceutical analysis represents 
a major step in terms of quality assurance. The developed 
HPTLC technique is precise, specific and accurate. Statistical 
analysis proves that the method is suitable for the analysis of 
Pregabalin and Amitriptyline Hydrochloride as bulk drug 
and in pharmaceutical formulation without any interference 
from the excipients. It was concluded that the developed 
method offered several advantages such as rapid, cost 
effective, simple mobile phase and sample preparation steps 
and improved sensitivity made it specific, reliable and easily 
reproducible in any quality control setup providing all the 
parameters are followed accurately for its intended use. 
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